635 A novel site-directed chemical conjugation technology confers antitumor activity via native Fc receptor to plasma immunoglobulin by attaching tumor binders

• Rajat Varma,
• Christian Vidal,
• Michael Cukan,
• Lawrence Iben,
• Tanya Berbasova,
• Ada Vaill,
• Anna Bunin,
• Ann Marie Rossi,
• David Trinh,
• Katy McGrath,
• Enrique Alvarez,
• Matthew Welsch,
• Luca Rastelli

Affiliations

Rajat Varma

Kleo Pharmaceuticals, New Haven, CT, USA

Christian Vidal

Kleo Pharmaceuticals, New Haven, CT, USA

Michael Cukan

Kleo Pharmaceuticals, New Haven, CT, USA

Lawrence Iben

Kleo Pharmaceuticals, New Haven, CT, USA

Tanya Berbasova

Kleo Pharmaceuticals, New Haven, CT, USA

Ada Vaill

Kleo Pharmaceuticals, New Haven, CT, USA

Anna Bunin

Kleo Pharmaceuticals, New Haven, CT, USA

Ann Marie Rossi

Kleo Pharmaceuticals, New Haven, CT, USA

David Trinh

Kleo Pharmaceuticals, New Haven, CT, USA

Katy McGrath

Kleo Pharmaceuticals, New Haven, CT, USA

Enrique Alvarez

Kleo Pharmaceuticals, New Haven, CT, USA

Matthew Welsch

Kleo Pharmaceuticals, New Haven, CT, USA

Luca Rastelli

Kleo Pharmaceuticals, New Haven, CT, USA